Based on the ProShares UltraShort Nasdaq Biotechnology stock forecast from 0 analysts, the average analyst target price for ProShares UltraShort Nasdaq Biotechnology is not available over the next 12 months. ProShares UltraShort Nasdaq Biotechnology’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of ProShares UltraShort Nasdaq Biotechnology is Bullish , which is based on 6 positive signals and 2 negative signals. At the last closing, ProShares UltraShort Nasdaq Biotechnology’s stock price was USD 17.70. ProShares UltraShort Nasdaq Biotechnology’s stock price has changed by -3.49% over the past week, +9.40% over the past month and -5.44% over the last year.
No recent analyst target price found for ProShares UltraShort Nasdaq Biotechnology
No recent average analyst rating found for ProShares UltraShort Nasdaq Biotechnology
Company Overview ProShares UltraShort Nasdaq Biotechnology
The fund invests in financial instruments that ProShare Advisors believes, in combination, should produce daily returns consistent with the Daily Target. The index is a modified capitalization weighted index that includes securities of Nasdaq listed companies that are classified as either biotechnology or pharmaceutical. The fund is non-diversified. Read Less
The fund invests in financial instruments that ProShare Advisors believes, in combination, should produce daily returns consistent with the Daily Target. The index is a modified capitalization weighted index that includes securities of Nasdaq listed companies that are classified ...Read More
Frequently Asked Questions About ProShares UltraShort Nasdaq Biotechnology (BIS) Stock
Stock Target Advisor's fundamental analysis for ProShares UltraShort Nasdaq Biotechnology's stock is Bullish .
BIS stock's dividend yield is 4.08%.
Our analysis grades BIS stock's dividend yield at F. This means that BIS stock's dividend yield is above 50% of the stocks in the Trading--Inverse Equity sector in the NSD exchange.
Based on this BIS may be a average dividend stock for its sector.
Unfortunately we do not have enough data on BIS's stock to indicate what its average analyst target is.
BIS stock's Price/Earning ratio is 8.04.
Our analysis grades BIS stock's Price / Earning ratio at A+. This means that BIS stock's Price/Earning ratio is above 0% of the stocks in the Trading--Inverse Equity sector in the NSD exchange.
Based on this BIS may be undervalued for its sector.
The last closing price of BIS's stock was USD 17.70.
The most recent market capitalization for BIS is USD 3.54M.
Unfortunately we do not have enough analyst data on BIS's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains ProShares UltraShort Nasdaq Biotechnology's stock.
As per our most recent records ProShares UltraShort Nasdaq Biotechnology has 0 Employees.
Sorry we do not have any infomation available on ProShares UltraShort Nasdaq Biotechnology's address.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Underpriced compared to book value
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Underpriced on free cash flow basis
The stock is trading low compared to its peers on a price to free cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Underpriced compared to earnings
The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Frequently Asked Questions About ProShares UltraShort Nasdaq Biotechnology (BIS) Stock
Stock Target Advisor's fundamental analysis for ProShares UltraShort Nasdaq Biotechnology's stock is Bullish .
BIS stock's dividend yield is 4.08%.
Our analysis grades BIS stock's dividend yield at F. This means that BIS stock's dividend yield is above 50% of the stocks in the Trading--Inverse Equity sector in the NSD exchange.
Based on this BIS may be a average dividend stock for its sector.
Unfortunately we do not have enough data on BIS's stock to indicate what its average analyst target is.
BIS stock's Price/Earning ratio is 8.04.
Our analysis grades BIS stock's Price / Earning ratio at A+. This means that BIS stock's Price/Earning ratio is above 0% of the stocks in the Trading--Inverse Equity sector in the NSD exchange.
Based on this BIS may be undervalued for its sector.
The last closing price of BIS's stock was USD 17.70.
The most recent market capitalization for BIS is USD 3.54M.
Unfortunately we do not have enough analyst data on BIS's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains ProShares UltraShort Nasdaq Biotechnology's stock.
As per our most recent records ProShares UltraShort Nasdaq Biotechnology has 0 Employees.
Sorry we do not have any infomation available on ProShares UltraShort Nasdaq Biotechnology's address.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for BIS !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
